The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues

The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical appl...

Full description

Saved in:
Bibliographic Details
Main Author: Editorial team Diabetes Mellitus
Format: Article
Language:English
Published: Endocrinology Research Centre 2016-05-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/7968
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850141116802793472
author Editorial team Diabetes Mellitus
author_facet Editorial team Diabetes Mellitus
author_sort Editorial team Diabetes Mellitus
collection DOAJ
description The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical application in patients with type 2 diabetes at high cardiovascular risk.
format Article
id doaj-art-5f7ca36e59854d25a5d206eef64bffb3
institution OA Journals
issn 2072-0351
2072-0378
language English
publishDate 2016-05-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-5f7ca36e59854d25a5d206eef64bffb32025-08-20T02:29:34ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782016-05-0119218218510.14341/DM2004156-617401The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issuesEditorial team Diabetes MellitusThe interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical application in patients with type 2 diabetes at high cardiovascular risk.https://www.dia-endojournals.ru/jour/article/view/7968empaglflozintype 2 diabetes mellituscardiovascular diseasemortalityempa-reg outcome trial
spellingShingle Editorial team Diabetes Mellitus
The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
Сахарный диабет
empaglflozin
type 2 diabetes mellitus
cardiovascular disease
mortality
empa-reg outcome trial
title The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_full The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_fullStr The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_full_unstemmed The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_short The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_sort interim experts counsil resolution on the empa reg outcome trial issues
topic empaglflozin
type 2 diabetes mellitus
cardiovascular disease
mortality
empa-reg outcome trial
url https://www.dia-endojournals.ru/jour/article/view/7968
work_keys_str_mv AT editorialteamdiabetesmellitus theinterimexpertscounsilresolutionontheemparegoutcometrialissues
AT editorialteamdiabetesmellitus interimexpertscounsilresolutionontheemparegoutcometrialissues